Takeda Finalizes $2.5B Antitrust Provision, Revising FY2025 Reported Net Profit to a Loss
TAK sits 17% above its 52-week low of $12.99.
Summary
Takeda has finalized a JPY 402.5 billion ($2.53 billion) provision for the AMITIZA antitrust litigation, revising its FY2025 reported net profit to a loss, though core results and FY2026 guidance remain unchanged.
Key Events · Legal and Risk Events · TAK
-
Formalizes Antitrust Provision
Takeda recorded an additional JPY 402.5 billion (approximately $2.53 billion) provision for legal proceedings related to the AMITIZA antitrust litigation.
-
FY2025 Reported Net Loss
The provision resulted in a JPY 344.151 billion reduction in FY2025 reported net profit, turning it into a net loss of JPY 152.125 billion.
-
No Impact on Core Results or FY2026 Guidance
The company emphasized that this revision does not affect its core financial results for FY2025 or its financial forecast and management guidance for FY2026.
-
Appeal Planned
Takeda intends to pursue post-trial motions and an appeal against the jury verdict.
Analysis · TAK · Life Sciences
This filing formalizes the financial impact of the previously announced AMITIZA antitrust jury verdict. Takeda has recorded an additional JPY 402.5 billion (approximately $2.53 billion) provision for legal proceedings, which significantly impacts its reported FY2025 financial results, turning a net profit into a net loss. While the company states this has no impact on its core financial results or FY2026 guidance, the substantial provision represents a material hit to its IFRS reported earnings and balance sheet for the past fiscal year. Takeda plans to appeal the verdict.
At the time of this filing, TAK was trading at $15.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $48B. The 52-week trading range was $12.99 to $18.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.